Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 10/20 | 0.40 |
| ▸ | CCNE1 | P24864 | 9/20 | 0.40 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.35 |
| ▸ | CDK1 | P06493 | 1/20 | 0.34 |
| ▸ | MITF | O75030 | 1/20 | 0.33 |
| ▸ | KLF5 | Q13887 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | GLA | P06280 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | DEGS1 | O15121 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30748793 | 0.88 | CDK2 (0.37) | CDK2CCNE1CDK1ABL1 | |
| SCHEMBL31691222 | 0.84 | CCNE1 (0.40) | CDK2CCNE1EGLN1ALDH1A1HTT | |
| SCHEMBL30748908 | 0.81 | ACACB (0.37) | CDK2CCNE1CDK1 | |
| SCHEMBL30749098 | 0.80 | CCNE1 (0.36) | CDK2CCNE1CDK1 | |
| SCHEMBL31691195 | 0.79 | CDK2 (0.36) | CDK2CCNE1CDK1KMT2A | |
| SCHEMBL30748888 | 0.79 | CCNE1 (0.39) | CDK2CCNE1EGLN1ALDH1A1HPGD | |
| SCHEMBL30749021 | 0.78 | CCNE1 (0.36) | CDK2CCNE1EGLN1ALDH1A1KMT2A | |
| SCHEMBL30749006 | 0.78 | EGLN1 (0.44) | CDK2CCNE1EGLN1ALDH1A1HPGD | |
| SCHEMBL30748954 | 0.78 | CDK2 (0.37) | CDK2CCNE1 | |
| SCHEMBL30749047 | 0.77 | CCNE1 (0.38) | CDK2CCNE1ALDH1A1HTTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250304571-A1 | BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF | SUZHOU KEEN THERAPEUTICS CO., LTD. (CN) | 2025-10-02 | — | — | US | disclosed |
| EP-4565588-A1 | BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF | Suzhou Keen Therapeutics Co., Ltd. (CN) | 2025-06-11 | — | — | EP | disclosed |
| WO-2023241620-A1 | BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF | SUZHOU KEEN THERAPEUTICS CO., LTD. (CN) | 2023-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250304571-A1 | BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF | VHL, BRCA1, TERT | CDK2 680/4885CCNE1 2310/4885EGLN1 202/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.